Details for Patent: 11,951,096
✉ Email this page to a colleague
Which drugs does patent 11,951,096 protect, and when does it expire?
Patent 11,951,096 protects OGSIVEO and is included in one NDA.
This patent has twenty-one patent family members in fourteen countries.
Drugs Protected by US Patent 11,951,096
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-001 | Nov 27, 2023 | RX | Yes | No | 11,951,096 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Subscribe | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-002 | Apr 4, 2024 | RX | Yes | No | 11,951,096 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Subscribe | ||||
| Springworks | OGSIVEO | nirogacestat hydrobromide | TABLET;ORAL | 217677-003 | Apr 4, 2024 | RX | Yes | Yes | 11,951,096 | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,951,096
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 119614 | ⤷ Subscribe | |||
| Australia | 2019461090 | ⤷ Subscribe | |||
| Australia | 2022342176 | ⤷ Subscribe | |||
| Brazil | 112022002392 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
